Two important therapies for ALL
Nivolumab in combination with azacitidine in patients with relapsed acute myeloid leukemia (AML)
Naval G. Daver
What makes the British Society for Haematology (BSH) Annual Scientific Meeting unique?
How the treatment of ALL is changing
How to manage infections after hematopoietic stem cell transplantation and the issue of resistance